A Woolcock, B Lundback, N Ringdal and LA Jacques
Institute of Respiratory Medicine, Prince Alfred Hospital, Camperdown, Australia.

A study was done to compare the efficacy and safety of the coprescription of salmeterol 50 microgram twice daily or 100 microgram twice daily with beclomethasone dipropionate (BDP) 500 micrograms twice daily (SALM 50 and SALM 100) with BDP 1,000 microgram twice daily (BDP 1,000) in patients with asthma not controlled by BDP 500 microgram twice daily (or the equivalent). Following a run-in period, 738 patients at 72 centers were randomized to treatment for 24 wk in a double-blind, parallel-group study during which they maintained a daily record of peak expiratory flow rates (PEFRs) and symptom scores. At about 40 of the centers, bronchial hyperresponsiveness (BHR) to histamine was measured during and at 3 and 14 d after stopping treatment. Both groups taking salmeterol showed an improvement of more than 45 L/min in their morning PEFR and 30 L/min in their evening PEFR, compared with respective improvements of 16 L/min and 6 L/min in the group taking BDP 1,000. Both the SALM 50 and SALM 100 groups had a significantly increased percentage of symptom-free and rescue-free days and nights compared with the BDP 1,000 group, and there was no difference between the two salmeterol groups. None of the treatments altered BHR. Exacerbation rates did not differ among the three groups. We conclude that in this selected group of symptomatic patients taking BDP 500 micrograms twice daily, the addition of salmeterol provides better improvement in lung function and symptom control, without altering BHR or increasing exacerbation rates, than does doubling the dose of BDP.

This article has been cited by other articles:

				E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, H. Ortega, and S. Yancey Meta-analysis: Effects of Adding Salmeterol to Inhaled Corticosteroids on Serious Asthma-Related Events Ann Intern Med, July 1, 2008; 149(1): 33 - 42. [Abstract] [Full Text] [PDF]

				A. P. Greening, D. Stempel, E. D. Bateman, and J. C. Virchow Managing asthma patients: which outcomes matter? Eur. Respir. Rev., June 1, 2008; 17(108): 53 - 61. [Abstract] [Full Text] [PDF]

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				M. Kaur, J. E. Chivers, M. A. Giembycz, and R. Newton Long-Acting 2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle Cells Mol. Pharmacol., January 1, 2008; 73(1): 203 - 214. [Abstract] [Full Text] [PDF]

				J. Loven, N. Svitacheva, A. Jerre, A. Miller-Larsson, and S. H. Korn Anti-inflammatory activity of {beta}2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor Eur. Respir. J., November 1, 2007; 30(5): 848 - 856. [Abstract] [Full Text] [PDF]

				S. T. Holgate, D. E. Davies, R. M. Powell, P. H. Howarth, H. M. Haitchi, and J. W. Holloway Local genetic and environmental factors in asthma disease pathogenesis: chronicity and persistence mechanisms Eur. Respir. J., April 1, 2007; 29(4): 793 - 803. [Abstract] [Full Text] [PDF]

				E. Naline, A. Trifilieff, R. A. Fairhurst, C. Advenier, and M. Molimard Effect of indacaterol, a novel long-acting {beta}2-agonist, on isolated human bronchi Eur. Respir. J., March 1, 2007; 29(3): 575 - 581. [Abstract] [Full Text] [PDF]

				J. Travers, S. Marsh, M. Williams, M. Weatherall, B. Caldwell, P. Shirtcliffe, S. Aldington, and R. Beasley External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax, March 1, 2007; 62(3): 219 - 223. [Abstract] [Full Text] [PDF]

				A. Deykin, M. E. Wechsler, H. A. Boushey, V. M. Chinchilli, S. J. Kunselman, T. J. Craig, E. DiMango, J. V. Fahy, M. Kraft, F. Leone, et al. Combination Therapy with a Long-Acting beta-Agonist and a Leukotriene Antagonist in Moderate Asthma Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 228 - 234. [Abstract] [Full Text] [PDF]

				S. R. Salpeter Safety of Long-Acting {beta}-Agonists. Ann Intern Med, November 7, 2006; 145(9): 708 - 710. [Full Text] [PDF]

				M. J. Lindberg Safety of long-acting beta-agonists. Ann Intern Med, November 7, 2006; 145(9): 706 - 707. [Full Text] [PDF]

				M. Humbert The Right Tools at the Right Time Chest, July 1, 2006; 130(1_suppl): 29S - 40S. [Abstract] [Full Text] [PDF]

				R. H. Green, C. E. Brightling, S. McKenna, B. Hargadon, N. Neale, D. Parker, C. Ruse, I. P. Hall, and I. D. Pavord Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Eur. Respir. J., June 1, 2006; 27(6): 1144 - 1151. [Abstract] [Full Text] [PDF]

				M. E. Wechsler, E. Lehman, S. C. Lazarus, R. F. Lemanske Jr., H. A. Boushey, A. Deykin, J. V. Fahy, C. A. Sorkness, V. M. Chinchilli, T. J. Craig, et al. beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 519 - 526. [Abstract] [Full Text] [PDF]

				K. Parameswaran Treatment Strategy for Asthma: One for All and All for One? Chest, February 1, 2006; 129(2): 221 - 223. [Full Text] [PDF]

				M. E. Strek Difficult asthma. Proceedings of the ATS, January 1, 2006; 3(1): 116 - 123. [Abstract] [Full Text] [PDF]

				G. P. Currie, D. K. C. Lee, and P. Srivastava Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma? Chest, October 1, 2005; 128(4): 2954 - 2962. [Abstract] [Full Text] [PDF]

				O. S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P. J. Barnes, and I. M. Adcock Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 704 - 712. [Abstract] [Full Text] [PDF]

				S. E. Overbeek, P. G. Mulder, S. M. Baelemans, H. C. Hoogsteden, and J.-B. Prins Formoterol Added to Low-Dose Budesonide Has No Additional Antiinflammatory Effect in Asthmatic Patients Chest, September 1, 2005; 128(3): 1121 - 1127. [Abstract] [Full Text] [PDF]

				E. K. Chu and J. M. Drazen Asthma: One Hundred Years of Treatment and Onward Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1202 - 1208. [Abstract] [Full Text] [PDF]

				M. Johnson Interactions between Corticosteroids and {beta}2-Agonists in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 200 - 206. [Abstract] [Full Text] [PDF]

				D. D. Sin, J. Man, H. Sharpe, W. Q. Gan, and S. F. P. Man Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis JAMA, July 21, 2004; 292(3): 367 - 376. [Abstract] [Full Text] [PDF]

				M. Gaga Fixed obstruction in severe asthma: not just a matter of time Eur. Respir. J., July 1, 2004; 24(1): 8 - 10. [Full Text] [PDF]

				M. Cazzola and R. Dahl Inhaled Combination Therapy With Long-Acting {beta}2-Agonists and Corticosteroids in Stable COPD Chest, July 1, 2004; 126(1): 220 - 237. [Abstract] [Full Text] [PDF]

				P. M. O'Byrne Pharmacologic Interventions to Reduce the Risk of Asthma Exacerbations Proceedings of the ATS, April 1, 2004; 1(2): 105 - 108. [Abstract] [Full Text] [PDF]

				C. Jenkins Formoterol as relief medication in asthma: the jury is still out Eur. Respir. J., November 1, 2003; 22(5): 723 - 724. [Full Text] [PDF]

				L. Bjermer, H. Bisgaard, J. Bousquet, L. M Fabbri, A. P Greening, T. Haahtela, S. T Holgate, C. Picado, J. Menten, S B. Dass, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial BMJ, October 18, 2003; 327(7420): 891. [Abstract] [Full Text] [PDF]

				H. A. Jenkins, C. Cool, S. J. Szefler, R. Covar, S. Brugman, E. W. Gelfand, and J. D. Spahn Histopathology of Severe Childhood Asthma: A Case Series Chest, July 1, 2003; 124(1): 32 - 41. [Abstract] [Full Text] [PDF]

				G.P. Currie, C.M. Jackson, S.A. Ogston, and B.J. Lipworth Airway-stabilizing effect of long-acting {beta}2-agonists as add-on therapy to inhaled corticosteroids QJM, June 1, 2003; 96(6): 435 - 440. [Abstract] [Full Text] [PDF]

				U. G. Lalloo, J. Malolepszy, D. Kozma, K. Krofta, J. Ankerst, B. Johansen, and N. C. Thomson Budesonide and Formoterol in a Single Inhaler Improves Asthma Control Compared With Increasing the Dose of Corticosteroid in Adults With Mild-to-Moderate Asthma Chest, May 1, 2003; 123(5): 1480 - 1487. [Abstract] [Full Text] [PDF]

				D B Price, D Hernandez, P Magyar, J Fiterman, K M Beeh, I G James, S Konstantopoulos, R Rojas, J A van Noord, M Pons, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax, March 1, 2003; 58(3): 211 - 216. [Abstract] [Full Text] [PDF]

				A.S. Buist Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes Eur. Respir. J., January 1, 2003; 21(39_suppl): 30S - 35s. [Abstract] [Full Text] [PDF]

				P.K. Jeffery, P. Venge, M.J. Gizycki, I. Egerod, R. Dahl, and P. Faurschou Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study Eur. Respir. J., December 1, 2002; 20(6): 1378 - 1385. [Abstract] [Full Text] [PDF]

				S. O'Sullivan, L. Cormican, M. Murphy, L. W. Poulter, and C. M. Burke Effects of Varying Doses of Fluticasone Propionate on the Physiology and Bronchial Wall Immunopathology in Mild-to-Moderate Asthma Chest, December 1, 2002; 122(6): 1966 - 1972. [Abstract] [Full Text] [PDF]

				N. J. Vanacker, E. Palmans, R. A. Pauwels, and J. C. Kips Effect of Combining Salmeterol and Fluticasone on the Progression of Airway Remodeling Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1128 - 1134. [Abstract] [Full Text] [PDF]

				F M Spoelstra, D S Postma, H Hovenga, J A Noordhoek, and H F Kauffman Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts Thorax, March 1, 2002; 57(3): 237 - 241. [Abstract] [Full Text] [PDF]

				R Manocha, G B Marks, P Kenchington, D Peters, and C M Salome Sahaja yoga in the management of moderate to severe asthma: a randomised controlled trial Thorax, February 1, 2002; 57(2): 110 - 115. [Abstract] [Full Text] [PDF]

				P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting {beta}2-agonists and corticosteroids Eur. Respir. J., January 1, 2002; 19(1): 182 - 191. [Abstract] [Full Text] [PDF]

				S.-E. DAHLEN, K. MALMSTROM, E. NIZANKOWSKA, B. DAHLEN, P. KUNA, M. KOWALSKI, W. R. LUMRY, C. PICADO, D. D. STEVENSON, J. BOUSQUET, et al. Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 9 - 14. [Abstract] [Full Text] [PDF]

				N. Roche, T. Lepage, J. Bourcereau, and P. Terrioux Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease Eur. Respir. J., December 1, 2001; 18(6): 903 - 908. [Abstract] [Full Text] [PDF]

				J. Malolepszy, G. Boszormenyi Nagy, O. Selroos, P. Larsson, and R. Brander Safety of formoterol Turbuhaler(R) at cumulative dose of 90 {micro}g in patients with acute bronchial obstruction Eur. Respir. J., December 1, 2001; 18(6): 928 - 934. [Abstract] [Full Text] [PDF]

				P. M. O'BYRNE, P. J. BARNES, R. RODRIGUEZ-ROISIN, E. RUNNERSTROM, T. SANDSTROM, K. SVENSSON, and A. TATTERSFIELD Low Dose Inhaled Budesonide and Formoterol in Mild Persistent Asthma . The OPTIMA Randomized Trial Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1392 - 1397. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				D. M. STEINBACHER and M. GLICK The dental patient with asthma: An update and oral health considerations J Am Dent Assoc, September 1, 2001; 132(9): 1229 - 1239. [Abstract] [Full Text] [PDF]

				S. Holt, A. Suder, M. Weatherall, S. Cheng, P. Shirtcliffe, R. Beasley, and A. Herxheimer Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Commentary: Dosage needs systematic and critical review BMJ, August 4, 2001; 323(7307): 253 - 253. [Abstract] [Full Text] [PDF]

				J. E. Fish, E. Israel, J. J. Murray, A. Emmett, R. Boone, S. W. Yancey, and K. A. Rickard Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy Chest, August 1, 2001; 120(2): 423 - 430. [Abstract] [Full Text] [PDF]

				A.J. Knox, Y.M. Zhu, and L. Pang Do long-acting {beta}2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma? Eur. Respir. J., June 1, 2001; 17(6): 1059 - 1061. [Full Text] [PDF]

				S.H. Korn, A. Jerre, and R. Brattsand Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells Eur. Respir. J., June 1, 2001; 17(6): 1070 - 1077. [Abstract] [Full Text] [PDF]

				S. C. Lazarus, H. A. Boushey, J. V. Fahy, V. M. Chinchilli, R. F. Lemanske Jr, C. A. Sorkness, M. Kraft, J. E. Fish, S. P. Peters, T. Craig, et al. Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial JAMA, May 23, 2001; 285(20): 2583 - 2593. [Abstract] [Full Text] [PDF]

				R. F. Lemanske Jr, C. A. Sorkness, E. A. Mauger, S. C. Lazarus, H. A. Boushey, J. V. Fahy, J. M. Drazen, V. M. Chinchilli, T. Craig, J. E. Fish, et al. Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial JAMA, May 23, 2001; 285(20): 2594 - 2603. [Abstract] [Full Text] [PDF]

				S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients Chest, May 1, 2001; 119(5): 1306 - 1315. [Abstract] [Full Text] [PDF]

				S. V. Bourdet and D. Williams Management Considerations for Chronic Asthma Journal of Pharmacy Practice, April 1, 2001; 14(2): 108 - 125. [Abstract] [PDF]

				M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]

				S.L. Jones, J.O. Cowan, E.M. Flannery, R.J. Hancox, G.P. Herbison, and D.R. Taylor Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Eur. Respir. J., March 1, 2001; 17(3): 368 - 373. [Abstract] [Full Text] [PDF]

				A. D. D'Urzo, K. R. Chapman, A. Cartier, F. E. Hargreave, M. Fitzgerald, and D. Tesarowski Effectiveness and Safety of Salmeterol in Nonspecialist Practice Settings Chest, March 1, 2001; 119(3): 714 - 719. [Abstract] [Full Text] [PDF]

				W. W. Busse and R. F. Lemanske Asthma N. Engl. J. Med., February 1, 2001; 344(5): 350 - 362. [Full Text] [PDF]

				L. PANG and A. J. KNOX Regulation of TNF-{alpha}-induced eotaxin release from cultured human airway smooth muscle cells by {beta}2-agonists and corticosteroids FASEB J, January 1, 2001; 15(1): 261 - 269. [Abstract] [Full Text] [PDF]

				W. W. Busse A 47-Year-Old Woman With Severe Asthma JAMA, November 1, 2000; 284(17): 2225 - 2233. [Full Text] [PDF]

				J. E. Kass and T. Bartter The Labyrinth of Asthma Therapy : Lost in the Choices Chest, October 1, 2000; 118(4): 891 - 893. [Full Text] [PDF]

				I. Aziz, A. M. Wilson, and B. J. Lipworth Effects of Once-Daily Formoterol and Budesonide Given Alone or in Combination on Surrogate Inflammatory Markers in Asthmatic Adults Chest, October 1, 2000; 118(4): 1049 - 1058. [Abstract] [Full Text] [PDF]

				C. Heuck, L. Heickendorff, and O. D Wolthers A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide Arch. Dis. Child., October 1, 2000; 83(4): 334 - 339. [Abstract] [Full Text] [PDF]

				C. Byrnes, S. Shrewsbury, P. J Barnes, and A. Bush Salmeterol in paediatric asthma Thorax, September 1, 2000; 55(9): 780 - 784. [Abstract] [Full Text]

				B. J. Lipworth, O. J. Dempsey, and I. Aziz Functional Antagonism With Formoterol and Salmeterol in Asthmatic Patients Expressing the Homozygous Glycine-16 {beta}2-Adrenoceptor Polymorphism Chest, August 1, 2000; 118(2): 321 - 328. [Abstract] [Full Text] [PDF]

				J. CHRISTIAN VIRCHOW Jr., A. PRASSE, I. NAYA, L. SUMMERTON, A. HARRIS, and The Zafirlukast Study Group Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 578 - 585. [Abstract] [Full Text] [PDF]